Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Plasma cell 3Other hematologic neoplasm 1Lymphoid 1Classical hematology 1Breast 1

Conditions

Anemia, Refractory, with Excess of Blasts 271Leukemia, Myeloid, Acute 258Myelodysplastic Syndromes 254Anemia 245Leukemia 228Neoplasms 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 182Leukemia, Myelomonocytic, Chronic 151Multiple Myeloma 138Venous Thromboembolism 137Myeloproliferative Disorders 131Leukemia, Lymphocytic, Chronic, B-Cell 126Lymphoma 119Lymphoma, Non-Hodgkin 118Thrombocytopenia 117Hodgkin Disease 103Anemia, Aplastic 97Febrile Neutropenia 86Hematologic Neoplasms 82Anemia, Refractory 82Primary Myelofibrosis 81Lymphoma, Follicular 81Congenital Abnormalities 81Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Blast Crisis 72Leukemia, Myeloid, Accelerated Phase 69Lymphoma, Mantle-Cell 68Neoplasms, Plasma Cell 66Myelodysplastic-Myeloproliferative Diseases 65

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fractures, Spontaneous × Classical hematology × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡